期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 7, 页码 3560-3577出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c02239
关键词
-
资金
- University Grants Commission, Basic Science Research [F.18-1/2011(BSR)]
- Science and Engineering Research Board of the Department of Science and Technology, New Delhi, India [EMR/2016/597 001984]
Nimbolide, a major limonoid constituent of neem, has garnered research attention for its anticancer properties. It has been shown to inhibit proliferation of cancer cells, overcome multidrug resistance, and enhance therapeutic outcomes. Nimbolide's ability to modulate signaling networks and molecular targets make it a valuable addition to the anticancer drug arsenal.
Nimbolide, a major limonoid constituent of Azadirachta indica, commonly known as neem, has attracted increasing research attention owing to its wide spectrum of pharmacological properties, predominantly anticancer activity. Nimbolide is reported to exert potent antiproliferative effects on a myriad cancer cell lines and chemotherapeutic efficacy in preclinical animal tumor models. The potentiality of nimbolide to circumvent multidrug resistance and aid in targeted protein degradation broaden its utility in enhancing therapeutic modalities and outcome. Accumulating evidence indicates that nimbolide prevents the acquisition of cancer hallmarks such as sustained proliferation, apoptosis evasion, invasion, angiogenesis, metastasis, and inflammation by modulating kinase-driven oncogenic signaling networks. Nimbolide has been demonstrated to abrogate aberrant activation of cellular signaling by influencing the subcellular localization of transcription factors and phosphorylation of kinases in addition to influencing the epigenome. Nimbolide, with its ever-expanding repertoire of molecular targets, is a valuable addition to the anticancer drug arsenal.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据